References
- Phillips L S, Langer R D. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83: 558–566
- Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006; 15: 35–44
- Pines A, Sturdee D W, Birkhauser M, on behalf of the International Menopause Society. More data on hormone therapy and coronary heart disease: Comments on recent publications from the WHI and Nurses' Health Study. Climacteric 2006; 9: 75–76
- Salpeter S R, Walsh J ME, Greyber E, Salpeter E E. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 2006; 21: 363–366
- Salpter S R, Walsh M E, Greyber E, Ormiston T M, Salpeter E E. Mortality associated with hormone therapy in younger and older women. J Gen Intern Med 2004; 19: 791–804
- Koh K K. Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy?. Int J Cardiol 2003; 87: 1–8
- MacLennan A H, Broadbent J L, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. 2004, Issue 4, Cochrane Database of Systematic Reviews, Art. No CD002978. DOI: 10.1002/14651858.CD002978.pub2
- Anderson G L, Chlebowski R T, Rossouw J E, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial plus progestin. Maturitas 2006; 55: 103–105
- MacLennan A H, Sturdee D W. Towards safer women, safer doses, safer routes and safer timing of administration of safer menopausal therapies. Climacteric 2005; 8: 1–2
- Sturdee D W, MacLennan A H. Prevention of osteoporosis is still a valid aim for hormone therapy. Climacteric 2005; 8: 97–98
- MacLennan A H, Wilson D H, Taylor A W. Hormone replacement therapy use over a decade in an Australian population. Climacteric 2002; 5: 351–356
- Solomon D H, Avorn J, Katz J N, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 2414–2419
- Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise – was it inevitable?. Climacteric 2002; 5: 317–325
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
- The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701–1712
- Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy; detection bias and resolution of discrepant findings in two Women's Health Initiative studies. Climacteric 2006; 9: 416–420
- Harman S M, Brinton E, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3–12
- Sturdee D W, MacLennan A H. Should epidemiology, the media and quangos determine clinical practice?. Climacteric 2004; 7: 1–2